- Home
- CNTX vs LYV Comparison
CNTX vs LYV Comparison
Compare CNTX & LYV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- LYV
- Stock Information
- Founded
- CNTX 2015
- LYV 2005
- Country
- CNTX United States
- LYV United States
- Employees
- CNTX 9
- LYV N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- LYV Services-Misc. Amusement & Recreation
- Sector
- CNTX Health Care
- LYV Consumer Discretionary
- Exchange
- CNTX Nasdaq
- LYV Nasdaq
- Market Cap
- CNTX 76.5M
- LYV N/A
- IPO Year
- CNTX 2021
- LYV N/A
- Fundamental
- Price
- CNTX $1.02
- LYV $132.59
- Analyst Decision
- CNTX Strong Buy
- LYV Strong Buy
- Analyst Count
- CNTX 4
- LYV 16
- Target Price
- CNTX $7.38
- LYV $144.63
- AVG Volume (30 Days)
- CNTX 234.3K
- LYV 2.5M
- Earning Date
- CNTX 11-06-2024
- LYV 11-11-2024
- Dividend Yield
- CNTX N/A
- LYV N/A
- EPS Growth
- CNTX N/A
- LYV N/A
- EPS
- CNTX N/A
- LYV 0.89
- Revenue
- CNTX N/A
- LYV $23,315,469,000.00
- Revenue This Year
- CNTX N/A
- LYV $2.91
- Revenue Next Year
- CNTX N/A
- LYV $14.88
- P/E Ratio
- CNTX N/A
- LYV $149.45
- Revenue Growth
- CNTX N/A
- LYV 9.99
- 52 Week Low
- CNTX $0.89
- LYV $86.67
- 52 Week High
- CNTX $2.75
- LYV $141.18
- Technical
- Relative Strength Index (RSI)
- CNTX 17.93
- LYV 47.57
- Support Level
- CNTX $1.17
- LYV $133.80
- Resistance Level
- CNTX $1.61
- LYV $138.56
- Average True Range (ATR)
- CNTX 0.11
- LYV 2.81
- MACD
- CNTX -0.03
- LYV -1.23
- Stochastic Oscillator
- CNTX 9.15
- LYV 6.30
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.